Literature DB >> 8675154

High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.

D Ferro1, C Quintarelli, A Lattuada, R Leo, M Alessandroni, P M Mannucci, F Violi.   

Abstract

The aim of this study was to evaluate whether there is endothelial dysfunction in patients with cirrhosis and to detect the mechanism that may account for it. We measured plasma levels of von Willebrand factor (vWF), a marker of endothelial perturbation, and endotoxin, which releases vWF from endothelial cells in vitro, in 32 patients (18 men, 14 women, aged 39-70 years) with cirrhosis classified as mild (class A, n = 10), moderate (class B, n = 16), or severe (class C, n = 6) according to Child-Pugh's classification. vWF antigen (P < .0001) and endotoxemia (P < .0001) progressively increased from A to class C; but the increase of vWF antigen was not strictly related to liver failure, as shown by the lack of correlation between vWF and several indexes of liver protein synthesis. Analysis of the vWF subunit showed no sign of proteolytic fragmentation of the molecule. Multimeric analysis indicated intact vWF multimeric structure. In all patients, there was a strong correlation between vWF antigen and endotoxemia (rho = .92; P = .0001). In 20 selected patients, vWF antigen and endotoxemia were measured before and after 7 days of standard therapy (n = 10) or standard therapy plus nonabsorbable antibiotics. There was a significant decrease of vWF antigen (P < .02) concomitantly with the decrease of endotoxemia (P < .006) in patients taking nonabsorbable antibiotics. Human umbilical vein endothelial cells incubated in vitro with 125 to 500 pg/mL endotoxin released vWF antigen into the medium dose dependently. These results demonstrate that there is endothelial perturbation in cirrhosis and that endotoxemia may play a key role in its occurrence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675154     DOI: 10.1002/hep.510230613

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation.

Authors:  Andreas Wannhoff; Conrad Rauber; Kilian Friedrich; Christian Rupp; Wolfgang Stremmel; Karl Heinz Weiss; Peter Schemmer; Daniel N Gotthardt
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

Review 2.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  Enhanced expression of monocyte tissue factor in patients with liver cirrhosis.

Authors:  M Saliola; R Lorenzet; D Ferro; S Basili; C Caroselli; A D Santo; M Sallese; F Violi
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 4.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

5.  Von Willebrand factor deficiency reduces liver fibrosis in mice.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Dafna J Groeneveld; Ton Lisman; James P Luyendyk
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-17       Impact factor: 4.219

6.  von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.

Authors:  Georgios N Kalambokis; Gerasimos Baltayiannis; Dimitrios Christodoulou
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

7.  Significant Association between Serum Levels of Von Willebrand Factor (vWF) Antigen with Stages of Cirrhosis.

Authors:  Vural Taner Yilmaz; Dinc Dincer; Ali Berkant Avci; Ramazan Cetinkaya
Journal:  Eurasian J Med       Date:  2015-02

8.  Effects of Portal Vein Thrombosis on the Outcomes of Liver Cirrhosis: A Mexican Perspective.

Authors:  Vania Cruz-Ramón; Paulina Chinchilla-López; Oscar Ramírez-Pérez; Nahum Méndez-Sánchez
Journal:  J Transl Int Med       Date:  2017-12-29

Review 9.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 10.  Venous thromboembolism in cirrhosis.

Authors:  Zhineng J Yang; Karen A Costa; Enrico M Novelli; Roy E Smith
Journal:  Clin Appl Thromb Hemost       Date:  2012-10-17       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.